David Hallal (L) and George Daley (Hallal photo: Bertrand Guay/AFP via Getty Images)
August 4, 2022 11:00 AM EDT
People
Startups
Cell/Gene Tx

David Hal­lal's El­e­vate­Bio launch­es new com­pa­ny to 'dis­rup­t' off-the-shelf cell ther­a­py, but pro­vides few oth­er de­tails

Max Gelman

Senior Editor

David Hal­lal’s El­e­vate­Bio is launch­ing a new com­pa­ny Thurs­day as it looks to con­tin­ue mak­ing its mark in the cell and gene ther­a­py spaces. But …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times